eGenesis: $191 Million (Series D) Secured To Develop Engineered Organs For Addressing Transplant Shortages
By Amit Chowdhry ● Sep 4, 2024
eGenesis, a biotechnology company that is developing human-compatible engineered organs to address the global organ shortage, announced today the closing of a $191 million Series D financing. The funding was led by Lux Capital, with participation from existing investors ARCH Ventures, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, and Leaps by Bayer, and new investors DaVita, Eisai Innovation, NATCO Pharmaceuticals, and Parkwood Corporation.